Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Small RNA molecule may hold key to understanding cataracts

NCT ID NCT07672899

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This study investigates whether a small RNA molecule called tRF-31 is linked to the severity of age-related cataracts. Researchers will collect lens tissue from 200 adults undergoing routine cataract surgery and measure tRF-31 levels. The goal is to see if higher or lower levels of tRF-31 correspond to harder cataracts or affect nearby eye cells.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If links between tRF-31 levels and cataract hardness are confirmed, this could point toward new ways to predict or slow cataract progression.
What could go wrong
This is an observational study, not a treatment trial. It only looks for correlations, so it cannot prove cause or lead directly to a therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of adult patients over 18 years of age who have been clinically diagnosed with age-related cataract (ARC) and are scheduled to undergo routine phacoemulsification combined with intraocular lens implantation at the Eye Center of the Second Affiliated Hospital, Zhejiang University School of Medicine.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients older than 18 years. Clinically diagnosed with age-related cataract (ARC) and have clear surgical indications for routine phacoemulsification combined with intraocular lens (IOL) implantation. Scheduled to undergo cataract extraction and intraocular lens implantation. Completed routine preoperative corneal endothelial specular microscopy, providing objective data including cell density, coefficient of variation of cell area, and the proportion of hexagonal cells. Provided signed written informed consent. Exclusion Criteria: History of ocular trauma, glaucoma, episodes of active uveitis, or previous intraocular surgery. Presence of severe systemic diseases rendering the patient unsuitable for surgery. Poor patient compliance or coexisting psychiatric disorders. Severe systemic metabolic syndromes (e.g., diabetes). Diagnosis of high myopia. Current participation in other clinical trials or likelihood of being lost to follow-up.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Age-related cataract are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Second Affiliated Hospital of Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, 310009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.